prednisolone; thiopurines; biologics). Rates are expressed as counts per 1,000 clinical events.

**Results** Comparing Apr-Jun 2020 (post-COVID) to Apr-Jun 2019 (pre-COVID): Total clinical event fell (9975 to 8208; -18%), with a sharp drop in F2F OPD (3436 to 1203; -65%) accompanied by a compensatory rise in non-F2F (1777 to 3161; +78%). Rate of new diagnoses fell (49 to 13 per 1,000 events; -74%). Prescription rates reduced sharply for thiopurines (26 to 5; -81%), with lesser reductions for biologics (89 to 55; -38%) and oral prednisolone (25 vs 20; -20%) but with a rise for non-prednisolone steroids (5 vs 8; +60%). No change in relative proportion of different biologic classes.

**Conclusions** Records of patient contacts were reduced in the immediate post-COVID period with a rapid shift from F2F to non-F2F. The drop in new patient records may reflect delayed pathways. Prescribing trends suggest a selective reduction in thiopurine and some shift from systemic to more topically-acting steroids. Longer term trends will be presented.

**Acknowledgements** Presented on behalf of sites collaborating in the UK IBD Registry.

---

**PMO-38 CONCOMITANT 5-AMINOSALICYLATE USE IN INFLAMMATORY BOWEL DISEASE PATIENTS ON BIOLOGIC THERAPY: A PRELIMINARY COST ANALYSIS**

Khai Leow*, Ramanan Gukathasan, Madeleine Bates, Sarah Alfred, Alison Danahay, Vivek Chhaya. University Hospitals Sussex NHS Foundation Trust, Worthing, UK

10.1136/gutjnl-2021-BSG.177

**Introduction** Despite the rapidly evolving therapeutic armamentarium for inflammatory bowel disease (IBD), 5-aminosalicylates (5-ASAs) are still widely utilised as induction therapy and in maintenance of remission. Emerging data advocating the withdrawal of 5-ASAs in patients receiving biologic therapy1-4 presented an opportunity for us to evaluate local practice in honing a value-based healthcare model.

**Methods** IBD patients receiving biologic therapy from December 2019 to December 2020 were identified via the Blueteq High Cost Drugs system. A retrospective analysis was then carried out, aided by a pre-designed proforma. Data on patient demographics, IBD subtype, type of biologic therapy and concomitant 5-ASA use including the brand name, daily dose and subsequent annual cost were collected.

**Results** 382 patients were on biologic therapy over the 12-month period, consisting of 204 males (53.4%) and 178 females (46.6%). A significant proportion were treated for Crohn’s disease (n=245, 64.1%), followed by ulcerative colitis (n=131, 34.3%) and IBD-unclassified (n=6, 1.6%). Adalimumab therapy was encountered in 151 cases (39.5%), Vedolizumab in 93 cases (24.3%), Infliximab in 79 cases (20.7%), Ustekinumab in 46 cases (12%), Tofacitinib in 9 cases (2.4%) and Golimumab in 4 cases (1%).

90 patients on biologic therapy were on concomitant 5-ASAs (23.6%). The vast majority suffered from ulcerative colitis (n=65, 72.2%), followed by Crohn’s disease (n=23, 25.6%) and IBD-unclassified (n=2, 2.2%). The total annual cost of 5-ASA therapy in this cohort was estimated at £73000.

**Conclusions** In a pressing economic landscape, discontinuation of 5-ASAs on escalation to biologic therapy may yield significant cost savings which could be reinvested into other aspects of patient care in IBD. Rationalisation of treatment will also address the issue of non-adherence due to polypharmacy and consequently lead to improved clinical outcomes.

**REFERENCES**


**PMO-39 FACTORS INFLUENCING DELAYS IN BIOLOGIC INITIATION IN INFAMMATORY BOWEL DISEASE**

1Eleanor Liu*, 2R Jatale, 3DeSilva, 3Hussain, 3Danjo, 3Sabine, 3Taylor, 3Sattar, 3Smith, 3Subramanian, 3Limi, 3Peninsula Acute Hospitals NHS Trust, Manchester, UK; 3Metropolitan Healthcare, Mumbai, India; 3Liverpool University Hospitals NHS Foundation Trust, Liverpool, UK

10.1136/gutjnl-2021-BSG.178

**Introduction** Biologics have transformed the treatment landscape in inflammatory bowel disease (IBD). Biologic initiation is a multi-step process often associated with delays. We aimed to describe factors affecting ‘decision to needle’ (D2N) time in a real-world IBD cohort, identifying barriers to efficient delivery of biologic therapy.

**Methods** This was a retrospective review of IBD patients commenced on biologic therapy between December 2018 and December 2019 at 2 large IBD centres. Inpatient biologic initiations were excluded. We recorded patient demographics, Harvey Bradshaw Index (HBI)/partial Mayo score (pMayo)/simple colitis activity index (SCCAI) and biochemical markers (faecal calprotectin [FC], C-reactive protein [CRP]). Dates were gathered on decision to treat, screening, blueteq approval and first dose. We used 21 days from decision to treat as a cut-off for determining D2N delay. Logistic regression examined associations between variables and D2N. Multivariate analysis was performed including variables with p<0.1 from univariate analysis.

**Results** We included 204 patients (mean age 45 years; range 18-82 (Table 1)) and median disease duration of 6 years. Mean Carlsson comorbidity index was 1 (range 0-7). Adalimumab was initiated in 93 patients (46%), ustekinumab:44 (22%), vedolizumab:34 (17%), infliximab:32 (16%) and golimumab:17. Median D2N time was 44.5 days overall, for intravenous (IV) drugs (n=110) 39.5 days (range 1-264), and subcutaneous (SC) drugs (n= 94) 50 days (range 8-362). There were no significant associations in D2N time with age (p=0.478) or IBD diagnosis (p=0.739). SC initiation was significantly associated with D2N time on univariate (p=0.007), but not on multivariate analysis. Odds of D2N delay were lower with Crohn’s disease (p<0.01) and baseline CRP>5 (p=0.008).